Home / Going-concern warnings / Protagenic Therapeutics, Inc.\new
Filed 2026-08-14 路 Form 10-K 路 Accession 0001493152-26-038255 nano
Price before filing: $0.36 (2026-08-13 close, split/dividend-adjusted)
Market cap at flag: $696,556 (2026-08-14) 路 Latest: $1.4M (2026-10-16)
| Window | PTIX | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | +130.6% | -2.2% | +132.7% | 2026-09-14 |
| 90 days | pending | pending | until 2026-11-12 | |
| 180 days | pending | pending | until 2027-02-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 1 insider bought $7K (4 purchases)
30 days after: 1 insider bought $24K (3 purchases)
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2026-07-30 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF., Director | Purchase | 26,291 | $0.18 | $5K | no | Form 4 |
| 2026-08-05 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF, Director | Purchase | 5,000 | $0.26 | $1K | no | Form 4 |
| 2026-08-06 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF, Director | Purchase | 685 | $0.22 | $151 | no | Form 4 |
| 2026-08-11 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF, Director | Purchase | 2,220 | $0.32 | $710 | no | Form 4 |
| 2026-08-14: red flag filed | |||||||
| 2026-08-19 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF, Director | Purchase | 2,700 | $0.35 | $945 | no | Form 4 |
| 2026-08-20 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF, Director | Purchase | 16,634 | $0.59 | $10K | no | Form 4 |
| 2026-08-21 | ARMEN GARO H EXEC. CHAIR & PRINCIPAL OFF, Director | Purchase | 20,000 | $0.65 | $13K | no | Form 4 |
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2026-05-16 to 2026-09-13. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Going-concern opinion issued by: GreenGrowth CPAs
Source: independent auditor report in Form 10-K (period 2026-03-31)
Why this score: in auditor's report; also within 90 days: Late annual report (NT 10-K)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.